HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
复制标题
DOI：
10.1002/cncr.30869
复制
发表时间：
2017-11-01
期刊：
影响因子：
6.2
通讯作者：
Khuri FR
中科院分区：
文献类型：
--
作者：
Pillai RN;Behera M;Berry LD;Rossi MR;Kris MG;Johnson BE;Bunn PA;Ramalingam SS;Khuri FR
人表皮生长因子受体2（HER2）突变已报告在肺腺癌。我们描述了肺癌突变联盟（LCMC）1007例患者中与HER2突变相关的患病率、临床特征和结局。晚期肺腺癌患者入组LCMC。评估肿瘤标本的诊断和充分性;在CLIA认证的实验室进行多重基因分型，以检查10个致癌驱动因素。查询LCMC数据库中的HER2突变患者，以获取人口统计学数据、治疗史和生命状态。我们进行了一项探索性分析，以评估接受HER2定向治疗的HER2突变患者的生存率。对920例患者进行了HER2突变检测; 24例患者（3%）携带20号外显子插入突变（95% CI 2 - 4%）。1例患者同时发生MET扩增。中位年龄为62岁，女性（n = 14）略多于男性（n = 10）。大多数患者为从不吸烟者（71%），在诊断时表现为晚期疾病。接受HER2靶向治疗的患者（n = 12）的中位生存期为2.1年，而未接受治疗的患者（n = 12）的中位生存期为1.4年（p = 0.48）。HER2突变患者的生存期低于LCMC队列中其他突变患者：接受靶向治疗的LCMC人群的中位生存期为3.5年，未接受靶向治疗的患者为2.4年。在LCMC中，在3%的肺腺癌患者中检测到HER2突变。应在该患者亚组中研究HER 2定向治疗。
Human epidermal growth factor receptor 2 (HER2) mutations have been reported in lung adenocarcinomas. We describe the prevalence, clinical features and outcomes associated with HER2 mutations in 1007 patients in the Lung Cancer Mutation Consortium (LCMC). Patients with advanced stage lung adenocarcinomas were enrolled to LCMC. Tumor specimens were assessed for diagnosis and adequacy; multiplexed genotyping was performed in CLIA certified laboratories to examine ten oncogenic drivers. The LCMC database was queried for patients with HER2 mutations to access demographic data, treatment history, and vital status. We conducted an exploratory analysis to evaluate survival of HER2 mutated patients treated with HER2 directed therapies. 920 patients were tested for HER2 mutations; 24 patients (3%) harbored exon 20 insertion mutations (95% CI 2 to 4%). One patient had a concurrent MET amplification. The median age was 62 years, with a slight predominance of females (n=14) over males (n=10). The majority of patients were never-smokers (71%) and presented with advanced disease at diagnosis. The median survival for patients that received HER2 targeted therapies (n=12) was 2.1 years compared to 1.4 years in those who did not (n=12) (p=0.48). Patients with HER2 mutations had inferior survival than the rest of the LCMC cohort with other mutations: the median survival was 3.5 years in LCMC population receiving targeted therapy and 2.4 years for patients not receiving targeted therapy. HER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC. HER2 directed therapies should be investigated in this subgroup of patients.
登录
查看更多内容
DOI：
10.1200/jco.2010.29.3126
发表时间：
2010-10-01
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Kelly RJ;Carter C;Giaccone G
通讯作者：
Giaccone G
DOI：
10.1097/jto.0b013e31827ce38e
发表时间：
2013-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Falchook GS;Janku F;Tsao AS;Bastida CC;Stewart DJ;Kurzrock R
通讯作者：
Kurzrock R
DOI：
10.1158/1078-0432.ccr-12-0912
发表时间：
2012-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Arcila ME;Chaft JE;Nafa K;Roy-Chowdhuri S;Lau C;Zaidinski M;Paik PK;Zakowski MF;Kris MG;Ladanyi M
通讯作者：
Ladanyi M
DOI：
10.1073/pnas.0808930106
发表时间：
2009-01-13
影响因子：
11.1
作者：
Perera, Samanthi A.;Li, Danan;Wong, Kwok-Kin
通讯作者：
Wong, Kwok-Kin
影响因子：
120.7
作者：
Kris, Mark G.;Johnson, Bruce E.;Berry, Lynne D.;Kwiatkowski, David J.;Iafrate, A. John;Wistuba, Ignacio I.;Varella-Garcia, Marileila;Franklin, Wilbur A.;Aronson, Samuel L.;Su, Pei-Fang;Shyr, Yu;Camidge, D. Ross;Sequist, Lecia V.;Glisson, Bonnie S.;Khuri, Fadlo R.;Garon, Edward B.;Pao, William;Rudin, Charles;Schiller, Joan;Haura, Eric B.;Socinski, Mark;Shirai, Keisuke;Chen, Heidi;Giaccone, Giuseppe;Ladanyi, Marc;Kugler, Kelly;Minna, John D.;Bunn, Paul A.
通讯作者：
Bunn, Paul A.